Form 8-K - Current report:
SEC Accession No. 0001493152-24-039016
Filing Date
2024-10-01
Accepted
2024-10-01 16:02:31
Documents
18
Period of Report
2024-10-01
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40785
2 ex99-1.htm EX-99.1 20594
3 ex99-1_001.jpg GRAPHIC 18729
4 ex99-1_002.jpg GRAPHIC 55444
5 ex99-1_003.jpg GRAPHIC 164033
  Complete submission text file 0001493152-24-039016.txt   617520

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE bctx-20241001.xsd EX-101.SCH 3750
7 XBRL DEFINITION FILE bctx-20241001_def.xml EX-101.DEF 29998
8 XBRL LABEL FILE bctx-20241001_lab.xml EX-101.LAB 36631
9 XBRL PRESENTATION FILE bctx-20241001_pre.xml EX-101.PRE 27021
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5668
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 241343174
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)